I could be wrong, but I think we are neglecting a key point in the process. Whilst the price is very clear on a per treatment basis, the potential co-pay from a patient is unknown.
1). Si made a reference to full reimbursement in the Bloomberg interview and then the point is mute
2). The company has been a champion in the space with the EAP and I took from the my Mesoblast they will help support patients to ensure no one is left behind. I personally took that as finance support if required, but that is a guess.
if anyone has worked in US pharma, I would love to hear your view on the topic.
@Pharmagang,
@otherperspective, SJup, phaedarius, dachopper, etc.
(20min delay)